Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GNBT intrest is growing, it is all over the boards and getting a lot of attention, it will go up steadily in the next few days, and then pops up huge imo.
GNBT is primed to run, watch this one.
BB are almost touching each other, only 0.8 gap, indicator show it has to move up shortly.
US approval in 4Q 2009 ??
I hope so ...
http://reports.finance.yahoo.com/w0?r=45713429:2
Developments Intelgenx announced that the FDA has finished its preliminary review and accepted Intelgenx’s NDA filing for CPI-300, a 450mg extended release Bupropion tablet. Impact Positive. Intelgenx is keeping to its timeline and we should see the tablet approved by Q4/09 and on the market by Q1/10. Comments The FDA has begun its full review of Intelgenx’s 450mg Bupropion tablet, which is excellent news for the company and maintains their timeline.
Five Fast-Growing Biotechs To Watch Right Now
http://www.biohealthinvestor.com/2009/07/five-growth-biotechs-to-watch-right-now-alny-fold-halo-aob-stem.html
Extreme FDA Trades: Another 18 Stocks Under 5 Bucks
http://seekingalpha.com/article/146954-extreme-fda-trades-another-18-stocks-under-5-bucks
medical device trades under 5$
http://seekingalpha.com/article/147092-medical-device-trades-7-stocks-under-5-bucks
GNBT i'm still thinking it is going to bounce from the 50ma. keep it on your watchlist
GNBT Could be the first bagger here, the news from friday looks nice.
It is having a lot of attention now by others here on IHUB, chart also looks nice and ready for a big jump the common days.
#msg-39121237
CYTR still trending up here, almost doubled, could go triple or more.
Bought GNBT @ 0.56 with the news today we will have more green the common days.
Generex's New Vaccine Technology Could Speed Flu Vaccine Availability
http://finance.yahoo.com/news/Generexs-New-Vaccine-pz-15628092.html?x=1&.v=1
Adding ONTY to my watchlist.
Oncothyreon Inc. (ONTY) announces Phase 3 Trial
June 22, 2009 · Filed Under General · Comments Off
Oncothyreon Inc. has announced that Merck KGaA of Darmstadt, Germany, has initiated a global 3 trial of Stimuvax. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.
The trial will be conducted in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer.
Oncothyreon opened Monday up 0.38 (16.67%) with a trade price of 2.66.
The phase 3 trial, named STRIDE (Stimulating immune response in advanced breast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia. The primary endpoint of STRIDE is progression-free survival. Overall survival, quality of life, tumor response and safety will also be assessed in this study.
Advanced-stage breast cancer remains a devastating and challenging disease and we urgently need new treatment options," said Dr. Larry Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, Massachusetts, and Principal Investigator of STRIDE. "If the results from the Phase 3 STRIDE study prove positive, this could make a difference for patients with hormone receptor positive metastatic breast cancer."
Joshua Sherman
CYTR, is still going up higher and higher.
still in and almost doubled, heading for a trip.
re IGXT ..Profitable by next year !!!!
http://www.intelgenx.com/_assets/pdf/Intelgenx-Presentation-2009.pdf
IGXT.OB = Multibagger Potential +++
This stock is vertualy unknown to investors. If you do your homework, you will clearly see that this stock will rise rapidly as soon as it gets noticed.
This is a real sleeper !!!! Please do your own Research .
Intelgenx Technologies (IGXT.OB)
MarketCap : 10,3 Mio US$
Price : 0,51 $
Shares Out : 20,85 M
Check out their fantastic Pipeline !
http://www.intelgenx.com/products/pipeline.html
Insider activity
http://finance.yahoo.com/q/it?s=IGXT.OB
RECENT OPERATIONAL HIGHLIGHTS ( May 2009)
- Filed NDA with U.S. Food and Drug Administration (FDA) - IntelGenx and Cary Pharmaceuticals filed a New Drug Application (NDA) under CFR 21 section 505(b)(2) for the CPI-300 antidepressant. CPI-300 is a new strength of a leading antidepressant that will provide a more convenient dosing option to patients with major depressive disorder ("MDD").
IntelGenx and Cary Pharmaceuticals entered into a Collaborative Agreement in November 2007 to jointly develop and commercialize CPI-300 using IntelGenx's proprietary oral delivery technology. Under the terms of the Collaborative Agreement, IntelGenx raised $2 million in March 2008 to fund completion of the product development and Cary Pharmaceuticals acted as the applicant for the submission of the NDA. Upon commercialization of the product, IntelGenx and Cary Pharmaceuticals would share profits.
- Earned Royalty Revenue for the first time in Company's History - IntelGenx earned royalty revenues of approximately $42.9 thousand in Q1, 2009 in respect of commercial activities in November and December 2008. Royalty revenues were earned from commercialization of the first product fully-developed by the Company, a prenatal multivitamin supplement marketed as Gesticare® in the USA, which was commercialized in November 2008.
- Announced Positive Phase 1(b) Clinical Study Results for Relivar - IntelGenx and Cannasat Therapeutics Inc., announced positive results for the Phase 1(b) clinical trial of Relivar, the first buccal dronabinol drug delivery product, which was developed using IntelGenx' proprietary AdVersa buccal delivery technology. Buccal delivery allows for drug absorption from the mouth directly into the bloodstream as opposed to the intestinal tract absorption seen with oral tablet technologies.
In this clinical trial, Relivar delivered twice the amount of dronabinol into the bloodstream versus the reference drug Marinol (as measured by AUC) with no increase in adverse events.
- Signed New Partnership Agreement with European Pharmaceutical Company - IntelGenx announced a new partnership with Circ Pharma Limited, a specialty pharmaceutical company based in Ireland, to develop and commercialize a novel drug for the treatment of hyperlipidemia.
In accordance with the Agreement, IntelGenx will be responsible for the formulation, manufacture and supply to Circ Pharma of the drug product. Circ Pharma will be responsible for commercialization of the product. Circ Pharma will fund the development of the product and IntelGenx will receive royalties from the product's sales.
In announcing the results, Horst Zerbe, President and Chief Executive Officer of IntelGenx, said:
"In the first few months of 2009 IntelGenx has already achieved a number of notable firsts in our corporate history: the 505(b)(2) NDA for the CPI-300 antidepressant was filed, and, for the first time, we earned sales and manufacturing royalties on the first product fully-developed by the Company.
IMO it is going to drop back to 50MA, this could be a good entry point. it is making higher highs an headed back up to dollar land.
This is the kind of DD i like, thanks Ed, pitty that i can't buy this one. because not i my brokers list.
Added GNBT to my watchlist, IMO it way undervalued and ready for a push to $$
Added on my watch list, with this news it can crawl up again.
NEW YORK (Dow Jones)--Shares of Aastrom Biosciences Inc. (ASTM) surged early Thursday after the U.S. Food and Drug Administration said it will allow the company to proceed with its clinical studies on a stem cell treatment for a severe form of chronic heart failure.
The FDA told Aastrom that it determined a patient death in the trial was unrelated to the company´s Cardiac Repair Cells, and therefore the agency was lifting a hold it had placed on Phase II trials on the treatment. The hold been in place since May 22.
Shares of Aastrom surged 12 cents, or 31.5%, to 50 cents in early trading.
The FDA, along with other investigators, determined that based on autopsy results and medical records, the patient death was caused by the progression of the disease and was unrelated to the Cardiac Repair Cell treatment.
The company doesn´t expect the delay to interfere with its goal of completing patient enrollment by the end of this year.
Hi, there's a small Canadian biotech with a drug being tested at the NCI (National Cancer Institiute) in Bethesda, Maryland. Name is Pharmagap and the symbol is GAP on the TSXV. Trades in the States under the symbol PHRGF. Previous tests done on human cancer cells in mice showed their lead drug was effective in treatment of cancer (see below). Results from NCI expecting sometime in the next 4 weeks.
PharmaGap Drug Effective Against Breast And Colon Cancer
Ottawa, Ontario/April 17, 2008 - PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company") released today the results of animal studies indicating statistically significant effectiveness of its lead cancer drug, PhG-alpha-1, in treating human breast and colon cancer.
Five separate test models, with a total of 240 mice, having previously been implanted with either human breast or colon cancer, were treated with PhG-alpha-1 at three doses, both singly and in combination with chemotherapeutic agents, or received saline solution or the chemotherapeutic agent alone as test controls.
In two of the test groups, one breast and one colon, the human cancer cells were implanted intravenously (breast) or intraperitoneally (colon), in order to simulate the natural metastases or spreading of the cancer cells within the body from one host organ to another. At the completion of a seven day period during which the cancer cell types used are known to establish tumours, the treatment regime began.
In three of the test groups, one breast and two different colon cell types, the human cancer cells were implanted subcutaneously. Once one or more palpable tumours were established, treatment began on a mouse by mouse basis, according to its assigned treatment group.
Breast cancer metastatic model
In this model, human breast cancer of the type Estrogen Receptor negative, which as a group represent the 30% of breast cancers which are not currently treatable by available drug therapies, were implanted into the bloodstream and provided with a seven day period to allow tumours to form. The type of cancer cells implanted is known to be highly invasive to the lungs, within a 3 to 5 day period following implantation. Following this establishment period of seven days, the treatment regime began in the eight groups of five mice.
In the group of 5 mice receiving PhG-alpha-1 at the dose of 1 mg/kg body weight, 4 of 5 (80%) when euthanized at the end of the trial period were observed to be tumour-free on post mortem examination, with no effect on other organs. The remaining mouse had developed a single small, friable (easily broken down) tumour. In the two control groups (saline and chemotherapy alone), 9 of 10 (90%) developed tumours, with only one surviving to the end of the trial and with ancillary organ damage to some degree. For all other treatment groups, 22 of 25 (88%) developed tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.
Breast cancer subcutaneous model
Using the same human breast cancer type, cancer cells were implanted beneath the skin and provided time to develop palpable tumours, following which treatment began.
In both single and combination therapy with a low dose of conventional chemotherapy agent, PhG-alpha-1 at 1 mg/kg body weight extended mouse survival relative to controls. In the cohorts receiving the combination treatment, the 5 and 10 mg/kg dosages showed however a longer extension of survival. More significantly, the cohorts receiving PhG-alpha-1 at each of the three dosing levels in the combination treatment showed a clear reduction in tumour volume compared to the cohort receiving chemotherapy alone, with a statistically significant dose response. The overall reduction in tumour volume compared to the control group receiving chemotherapy alone was approximately 58.7%.
Colon cancer metastatic model
Human colon cancer cells type LS180, known to be highly metastatic following implantation in the peritoneal cavity (the space containing the intestines, stomach and liver), were provided with a period of seven days in order to establish metastatic tumours on the liver, spleen, and other sites within the cavity. PhG-alpha-1 was administered intraperitoneally at three doses (1, 5, and 10 mg/kg body weight), alone and in combination with a conventional chemotherapeutic agent at sub-therapeutic dose, over up to a 98 day period. In the group receiving PhG-alpha-1 alone at the 10 mg/kg dose, an improvement in survival relative to the control group was observed from day 50 to 80. In the group receiving PhG-alpha-1 at 10 mg/kg in combination with chemotherapy, survival relative to the group receiving chemotherapy alone was evident throughout the test period.
Overall tumour incidence was 46% in the groups receiving PhG-alpha-1 alone, at all dosages, compared with 80% in the saline control group, and was 60% in groups receiving PhG-alpha-1 in combination therapy, compared to 100% for the chemotherapy control.
Measurement of VEGF serum levels (vascular endothelial growth factor, an angiogenic (growth of blood vessels) agent increasing tumour malignancy) confirmed earlier results showing reduction in VEGF levels following treatment with PhG-alpha-1.
Additional models
Analysis of data from two additional models using two different human colon cancer cell lines continue and results will be announced as they become available over the course of the next few weeks.
Previous tests showed the drug's effectiveness in delaying the ability of human cancer cells to form tumours in mice, when administration of PhG-alpha-1 alone or in combination with chemotherapeutic agents began immediately following the introduction of the cancer cells to the mouse test subject. The current round of testing just completed - known as an Established Tumour Study ("ETS") - mimics the therapeutic treatment regime found in clinical treatment of humans, in that the drug treatment regimen is commenced only after tumours are allowed to develop without treatment.
These test results provide positive indication that PhG-alpha-1 has the ability to be developed into an effective agent against cancer in test models designed to mimic real world therapy regimes encountered in clinical treatment of humans.
About PharmaGap Inc.
PharmaGap Inc. (TSX-V: GAP), based in Ottawa, ON, is a biotechnology company with a core focus on developing novel therapeutic compounds for the treatment of cancer. PharmaGap's research platform targets cellular signaling pathways controlled by protein kinase C (PKC) isoforms. PharmaGap's lead drug compound, PhGalpha1, is in preclinical development. The Company's strategy is to out-license drug compounds to larger life sciences companies at the preclinical stage. For more information please visit the Company's website at www.pharmagap.com.
For information relating to this release, please contact:
Robert McInnis, President & CEO
(613) 990-9551 bmcinnis@pharmagap.com
CYTR back on the move, big news here
CytRx's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity
in Animal Trial for Multiple Myeloma
Jun. 17, 2009
Business Editors/Medical Editors
LOS ANGELES--(BUSINESS WIRE)--Jun. 17, 2009--CytRx Corporation (NASDAQ:CYTR), a
biopharmaceutical research and development company engaged in the development
of high-value human therapeutics, today announced that tamibarotene, currently
under evaluation in a U.S. registration trial as a third-line treatment for
acute promyelocytic leukemia (APL), showed statistically significant anti-tumor
activity in human myeloma cells transplanted into animals. Multiple myeloma is
an incurable malignant tumor of the plasma cells of bone marrow. Results of the
trial were published in the June 2009 peer-reviewed journal Cancer Science
(Volume 100, No. 6, Pages 1137-1143).
"These results support our contention that tamibarotene's mechanism of
action may provide broad commercial potential as a therapeutic treatment beyond
APL to other cancers such as multiple myeloma," said Steven A. Kriegsman, CytRx
President and CEO. "Despite advances in therapies that improve the quality of
life and length of survival, many multiple myeloma patients experience severe
side effects from current therapies, prompting the need for additional
therapies."
"We are evaluating opportunities for a Phase 2 clinical program with
tamibarotene as a multiple myeloma therapy, as well as investigating
partnership prospects for developing and commercializing tamibarotene in the
U.S. for both multiple myeloma and APL," he added.
CytRx has the right to develop tamibarotene as a treatment for multiple
myeloma in Europe, and has the option to expand its license for the use of
tamibarotene for multiple myeloma and certain other oncology applications in
the U.S. Tamibarotene is currently approved for relapsed or refractory
treatment of APL in Japan.
The animal trial, conducted by an independent third party in Japan, was
designed to evaluate the activity of tamibarotene as a multiple myeloma
treatment alone and in combination with a glucocorticoid, a commonly prescribed
treatment for this disease. Five different human myeloma cell lines were
treated with tamibarotene alone, glucocorticoids alone, or tamibarotene +
glucocorticoids in cell culture. Tamibarotene by itself inhibited the growth of
these tumor cells two- to 10-fold more potently than all-trans retinoic acid
(ATRA), a less specific relative of tamibarotene which has previously been
shown to inhibit the growth of human myeloma cells. Importantly, the
combination of tamibarotene with glucocorticoids was found to show markedly
greater growth inhibition than either drug alone.
Human myeloma cells were then transplanted into mice with compromised immune
systems to study the tumor growth-inhibitory effects of these drugs. Both
tamibarotene and glucocorticoids by themselves reduced the rate of tumor
growth. However, the combination of tamibarotene with glucocorticoids showed a
synergistic interaction that resulted in markedly decreased tumor growth and
increased survival compared with either drug alone. Trial investigators
concluded that tamibarotene in this drug combination approach was among the
most promising potential therapeutic regimens for multiple myeloma, especially
in high-risk patients, and should be further investigated.
"Our drug tamibarotene is more stable and may have fewer adverse events than
ATRA, with both drugs demonstrating the ability to force certain types of
leukemia cells to cease growing uncontrollably and return to performing their
normal functions - a process known as terminal differentiation," said Jack
Barber Ph.D., CytRx's Chief Scientific Officer. "Multiple myeloma cells are
thought to grow uncontrollably due in part to a growth factor called IL-6.
Glucocorticoids are a potent inducer of cell death; however this benefit may be
offset by their known activation of IL-6 activity. Tamibarotene has previously
shown the ability to interfere with the normal functioning of IL-6, which could
be the foundation for the anti-proliferative effects of tamibarotene in
multiple myeloma, particularly in combination with glucocorticoids.
"We are delighted and encouraged by this proof of concept, which could
ultimately increase the potential market for tamibarotene," added Dr. Barber.
Some DD on PPHM.
http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/06-10-2009/0005041534&EDATE=
http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/06-03-2009/0005037588&EDATE=
http://seekingalpha.com/article/140342-fda-clinical-trial-updates-jnj-incy-medx-cytx-agn-pphm
No problem foggy!! Good board and good luck. Person Marked..Thanks
PS - If i find more DD on Biotechs i will surely post them here
Thanks on this one, if sheff is involved with the DD here it is going to be nice for sure.
Some DD on CYTR
CYTR CytRx initiated with a Mkt Outperform at Rodman & Renshaw; tgt $2 (0.55 +0.01)
Rodman & Renshaw initiates CYTR with a Mkt Outperform and price target of $2. Firm says the acquisition of Innovive Pharmaceuticals in 2008 has provided CYTR with a refreshed pipeline of products and a new therapeutic focus. Included are compounds such as Tamibarotene, in a pivotal Phase II study for Acute promyelocytic leukemia, which have the potential to reach the mkt in a relatively short period of time, thereby quickening the co's transition into a commercial biotech firm and bringing in early revs. Firm believes that the core molecular chaperone compounds that CYTR acquired through their acquisition of Biorex, and has further developed can provide value, despite facing some delays in their development. Also, firm reminds investors that CYTR currently holds a 46% stake in RXi Pharmaceuticals (RXII). With a current market capitalization of $67 mln, this stake is worth nearly $30 mln alone
If this stands and step up to the next phase, this will have a nice uptrend. so keep it on your radar.
http://clinicaltrials.gov/archive/NCT00520208/2009_06_01
http://apltrial.com/
I bought in on this one at 0.48 some time ago.
nice ones but please post some DD why this one could be the next runner.
CYTR back on the move, IMO this going to be a 2$ stock in a few months.
I will post some DD later
Some DD on HSKA
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6317327
at 05/06/09 filed 5X form 4 for a purchase of 50000 shares each
Imo this stock has strong grow potential in the next weeks and months.
Just take a look at it.
Hope your board does well. GNTA is a 50/50 play. 50% you lose but the other 50% could make you rich. You will be facing a possable R/S and FDA approval for their drug all at the same time. The drug genasense is through the 3 trial and looks like it works from a five year follow up report. Good DD on the GNTA board and should be looked at before investing. JT all in my opinion. good luck
Hello and welcome to my board.
In a search for a stock with high potential i came up in to the biotechnology sector. The stocks you invest in can be very risky but can also have nice returns. to name one DNDN up 1000% lately from March.
So if you like to spend some time,go find this next multidollar stock, stay here for a while and help us find the ONE.
I like honest trading, no Pumping or bashing of any kind here, it will be deleted and you are banned for good.
Hope to find here THE ONE that makes us all $$$$$$$$.
If any one would like to assist me please do and lets make this the number one board of Bio stocks on ihub.
United Nations Convention on Biological Diversity defines biotechnology as any technological application that uses biological systems, dead organisms, or derivatives thereof, to make or modify products or processes for specific use.
Biotechnology combines disciplines like genetics, molecular biology, biochemistry, embryology, and cell biology, which are in turn linked to practical disciplines like chemical engineering, information technology, and biorobotics. Patho-biotechnology describes the exploitation of pathogens or pathogen derived compounds for beneficial effect.
So this means that not only meds and pharma is allowed here.
Please do some DD when you post here because i dont like gambling.
Followers
|
4
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
39
|
Created
|
06/08/09
|
Type
|
Free
|
Moderators |
THIS BOARD IS CREATED FOR ANY BIOSTOCK WHO HAS THE POTENTIAL TO BE A MULTIBAGGER STOCK
www.bioportfolio.com/nasdaq/index.htm
http://www.bioportfolio.com/nasdaq/index.htm
www.biotechnology-stocks.com/introduction.cfm
www.biology.iupui.edu/biocourses/Biol540/1introCSS.html
seekingalpha.com/sector/biotech
A Very good blog
biotechnology-stock.blogspot.com/
Also a good link
www.ehow.com/how_2003662_biotech-mutual-funds.html
Bought at 0.48
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |